TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30578686
Drug: Antenatal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal insulin therapy (AIT)
Study: 30578686
Drug: 1-hour oral
Normalized name: 3α-(diphenylmethoxy)-1αH,5αH-tropane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour oral glucose tolerance test (OGTT)
Study: 30579045
Drug: Open-label antidepressant
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label antidepressant treatment for up to 24 months
Study: 30579270
Drug: Convection-enhanced delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convection-enhanced delivery (CED) using 124I-8H9, a radioimmunotherapeutic agent, with a mean infusate volume of 3.84-4.54 ml.
Study: 30579270
Drug: Convection-enhanced delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convection-enhanced delivery (CED) in the highest dose level.
Study: 30579327
Drug: Viscoelastic tests-guided
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscoelastic tests-guided therapy with synthetic factor concentrates
Study: 30580418
Drug: Mandibular repositioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular repositioning device (MRD) therapy
Study: 30580723
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy + TOBT
Study: 30580852
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy (mainly vitamin K antagonist)
Study: 30581606
Drug: Fludrocortisone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.4 mg per day for 7 days)
Study: 30582166
Drug: Preoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotic use (mean 27.8 ± 22.7 days out of 90 days prior to ESS)
Study: 30582166
Drug: Increased preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased preoperative antibiotic use
Study: 30582166
Drug: Preoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotic use
Study: 30584308
Drug: Tigecycline (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (initial dose 100 mg, then 50 mg q12h)
Study: 30584308
Drug: Imipenem/cilastatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (500 mg/500 mg or adjusted for renal dysfunction, q6h)
Study: 30585255
Drug: SAR405838 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR405838 200 mg QD plus pimasertib 45 mg BID
Study: 30585255
Drug: SAR405838 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR405838 200 mg QD plus pimasertib 60 mg QD or 45 mg BID
Study: 30586316
Drug: Sunitinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib administered once weekly at 300 mg
Study: 30586316
Drug: Sunitinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib administered once every 2 weeks at 700 mg
Study: 30586316
Drug: Sunitinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (both dosing schedules)
Study: 30586316
Drug: Sunitinib (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (once every 2 weeks at 700 mg)
Study: 30586692
Drug: Idarucizumab (5-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (5-g dose administered as 2 bolus infusions of 2.5 g no more than 15 minutes apart)
Study: 30588886
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral anticoagulant therapy (OACb)
Study: 30589495
Drug: tPA >20
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA >20 ng/mL
Study: 30589964
Drug: Bezafibrate add-on
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate add-on therapy
Study: 30590596
Drug: Phylloquinone repletion
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone repletion (∼500 µg phylloquinone/d)
Study: 30590596
Drug: Phylloquinone depletion
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone depletion (∼10 µg phylloquinone/d)
Study: 30591285
Drug: Co-medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-medications
Study: 30591548
Drug: DHEA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 100 mg/day orally in combination with an aromatase inhibitor (AI)
Study: 30591548
Drug: DHEA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 100 mg/day orally
Study: 30591982
Drug: Tarextumab 5
Normalized name: Tarextumab
DrugBank: Tarextumab (DB12104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarextumab 5 mg/kg weekly
Study: 30591982
Drug: Tarextumab 10
Normalized name: Tarextumab
DrugBank: Tarextumab (DB12104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarextumab 10 mg/kg every other week
Study: 30591982
Drug: Tarextumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarextumab 7.5 mg/kg every three weeks
Study: 30591982
Drug: Tarextumab 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarextumab 2.5 mg/kg weekly
Study: 30591982
Drug: Tarextumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarextumab 7.5 mg/kg every other week
Study: 30591982
Drug: Tarextumab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarextumab at doses <2.5 mg weekly and 7.5 mg/kg every other and every three weeks
Study: 30593513
Drug: Lapatinib (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (first-line treatment for patients with CNS metastasis at diagnosis)
Study: 30593513
Drug: Trastuzumab (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (first-line treatment for patients with CNS metastasis at diagnosis)
Study: 30593776
Drug: Daily aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily aspirin use
Study: 30596677
Drug: LivRelief Varicose
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LivRelief Varicose Vein Cream
Study: 30596901
Drug: Multifaceted infection
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted infection prevention and control (IPC) bundle including IPC training, text message reminders, alcohol hand rub, enhanced environmental cleaning, and weekly bathing with 2% chlorhexidine gluconate.
Study: 30597027
Drug: qPCR for
Approvals — FDA: no, EMA: no, PMDA: no
Description: qPCR for G. vaginalis and/or Atopobium vaginae above a threshold
Study: 30597509
Drug: Prolonged dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged dual anti-platelet therapy (DAPT)
Study: 30598343
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (15-minute continuous infusion of native GLP-1 (7-36) NH)
Study: 30598500
Drug: TKM-080301 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKM-080301 (0.3 mg/kg to 0.75 mg/kg, maximum tolerated dose redefined at 0.6 mg/kg)
Study: 30598642
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg-equivalent dose regimens
Study: 30600654
Drug: Live zoster
Normalized name: Varicella zoster vaccine (live/attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live zoster vaccine administered at 6-12 months after zoster illness
Study: 30600654
Drug: Live zoster
Normalized name: Varicella zoster vaccine (live/attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live zoster vaccine administered at 1-5 years after zoster illness
Study: 30603376
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine (23vPPV) during pregnancy
Study: 30603378
Drug: Dexamethasone as
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone as adjunctive treatment
Study: 30603797
Drug: Nintedanib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (150 mg or 200 mg oral twice daily) and Bevacizumab (15 mg/kg once intravenously every 3 weeks)
Study: 30605211
Drug: Avelumab, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study.
Study: 30605510
Drug: Inappropriate diagnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate diagnosis in a ventricular arrhythmia zone with enabled therapy
Study: 30605510
Drug: Inappropriate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate therapy recurrence
Study: 30605751
Drug: All dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose levels (DL1, DL2, DL3)
Study: 30606188
Drug: Physical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical and mental health symptom severity, psychiatric diagnosis, and psychopharmacological medication
Study: 30606236
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation by oral administering
Study: 30606236
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation through mid-gut transendoscopic enteral tubing (TET)
Study: 30607301
Drug: Pressurized intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin aerosol, median 2 interventions per patient (range 1-6).
Study: 30607629
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg once daily with trastuzumab 2 mg/kg and paclitaxel 80 mg/m²
Study: 30607889
Drug: Milrinone continuous
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone continuous infusions
Study: 30610196
Drug: Carfilzomib 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib 36 mg/m² combined with panobinostat
Study: 30610355
Drug: Postoperative radio(chemo)therapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radio(chemo)therapy
Study: 30610872
Drug: Neurotropic drugs
Normalized name: neurotrophin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotropic drugs (including opioids, sedatives, hypnotics, antidepressants)
Study: 30610872
Drug: Neurotropic drugs
Normalized name: neurotrophin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotropic drugs or cardiovascular drugs
Study: 30611192
Drug: Subclinical tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subclinical tuberculosis treatment
Study: 30611192
Drug: Active tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tuberculosis treatment
Study: 30611197
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA, propofol + remifentanil)
Study: 30611293
Drug: 2-HOBA acetate
Normalized name: 2-(Trimethylammonio)Acetate
DrugBank: 2-(aminomethyl)phenol (DB14855)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-HOBA acetate (up to 825 mg)
Study: 30612568
Drug: Standard oxaliplatin-based
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard oxaliplatin-based or irinotecan-based chemotherapy
Study: 30612710
Drug: Sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200 mg, intravenous, once every 3 weeks)
Study: 30612959
Drug: Hemostatic powder
Normalized name: collagen hemostat Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemostatic powder (TC-325/Hemospray) applied as monotherapy in 13 bleeding sites (25%)
Study: 30612959
Drug: Hemostatic powder
Normalized name: collagen hemostat Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemostatic powder (TC-325/Hemospray) applied as combination therapy in 22 bleeding sites (42.3%)
Study: 30612959
Drug: Hemostatic powder
Normalized name: collagen hemostat Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemostatic powder (TC-325/Hemospray) applied as rescue therapy in 17 bleeding sites (32.7%)
Study: 30614187
Drug: Circulating total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating total testosterone (TT) > 14.76 nmol/L
Study: 30614187
Drug: Circulating total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating total testosterone (TT) ≤ 14.76 nmol/L
Study: 30614939
Drug: Budesonide therapy
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide therapy (1 mg BID for 8 weeks)
Study: 30616617
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for drug sensitive and multidrug-resistant pulmonary TB
Study: 30616998
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg/day) plus Quercetin (1250 mg/day), three-days/week over three-weeks
Study: 30618179
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg once every 3 weeks for 2 years or until disease progression/unacceptable toxicity
Study: 30618764
Drug: Fixed Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Combination of Chinese Herbal Medicine
Study: 30618929
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen Therapy
Study: 30619077
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Stimulation (FES) for gait rehabilitation, details on dosage and duration not available
Study: 30619615
Drug: Micro-particle curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-particle curcumin 90 mg once daily for 6 months
Study: 30621615
Drug: Option B+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Option B+ (antiretroviral therapy throughout life)
Study: 30622509
Drug: Educational and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational and reminder-based intervention for adherence to direct oral anticoagulant treatment
Study: 30622667
Drug: Atosiban (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (administered continuously for 48 hours)
Study: 30623229
Drug: Intraperitoneal nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal nab-paclitaxel (IP) at a dose of 112.5 mg/m²
Study: 30623229
Drug: Intraperitoneal nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal nab-paclitaxel (IP) at doses 35-175 mg/m²
Study: 30623276
Drug: ontuxizumab 2-12
Normalized name: Ontuxizumab
DrugBank: Ontuxizumab (DB16270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ontuxizumab 2-12 mg/kg weekly (part 1)
Study: 30623276
Drug: ontuxizumab 4
Normalized name: Ontuxizumab
DrugBank: Ontuxizumab (DB16270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ontuxizumab 4 or 8 mg/kg weekly, or 12 mg/kg biweekly (part 2)
Study: 30624149
Drug: Methylprednisolone group
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone group (MG, N = 18; 500 mg in the CPB priming)
Study: 30624149
Drug: Methylprednisolone group
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone group (MG)
Study: 30624546
Drug: Larotrectinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larotrectinib (100 mg twice daily)
Study: 30624603
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g fish oil/d containing 1.9-2.2 g eicosapentaenoic acid and 1.1 g docosahexanoic acid for 6 weeks
Study: 30624668
Drug: Colistin methanesulfonate
Normalized name: Colistin methanesulfonic acid
DrugBank: Colistimethate (DB01111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin methanesulfonate 6 million IU (MIU) loading dose followed by 3 MIU every 8 hours
Study: 30626191
Drug: Technology-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology-based medication adherence support intervention (real-time adherence monitors linked to SMS text messages)
Study: 30626633
Drug: hs-cTnT at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT at presentation >14 ng/L
Study: 30626633
Drug: hs-cTnT at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT at presentation >52 ng/L
Study: 30626633
Drug: Initial cTn
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial cTn concentrations alone and in combination with early changes
Study: 30626746
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg mirtazapine daily for 7 days
Study: 30629195
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) for 2 weeks
Study: 30630355
Drug: Drug-Coated Balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Coated Balloon Treatment
Study: 30630632
Drug: Low-grade inflammation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-grade inflammation (CRP >1.0 mg/L to <10.0 mg/L)
Study: 30630885
Drug: Atezolizumab in
Normalized name: atezolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab in combination with paclitaxel, carboplatin, and bevacizumab
Study: 30630885
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with paclitaxel, carboplatin, and bevacizumab
Study: 30633573
Drug: Entospletinib 400
Normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entospletinib 400 mg BID
Study: 30634942
Drug: Afatinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (30 mg) as add-on to gemcitabine/cisplatin (80% standard dose)
Study: 30635165
Drug: Veliparib 40
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib 40 mg BID with gemcitabine 400 mg/m² and daily IMRT
Study: 30635336
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of palbociclib (75 mg) and paclitaxel (80 mg/m2)
Study: 30636101
Drug: hfTENS device
Approvals — FDA: no, EMA: no, PMDA: no
Description: hfTENS device (Quell, NeuroMetrix, Inc.) used daily for 3 months
Study: 30636249
Drug: Furosemide stress
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide stress test (FST) with a single dose of intravenous furosemide, 1.5 mg/kg at 3 h after allograft reperfusion
Study: 30637118
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement with milk
Study: 30637118
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement with food
Study: 30637118
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement on an empty stomach
Study: 30637118
Drug: Frozen fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen fish oil capsules prior to ingestion
Study: 30637784
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow transplantation (BMT) with reduced toxicity preparative regimen of busulfan (13.2 mg/kg) and fludarabine (175 mg/m2)
Study: 30638856
Drug: Burosumab (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burosumab (0.8 mg/kg) via subcutaneous injection every 2 weeks for 64 weeks, with possible increase to 1.2 mg/kg based on serum phosphorus levels.
Study: 30640659
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (four incremental doses)
Study: 30642285
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with 3 cycles of cisplatin and pemetrexed
Study: 30642285
Drug: Metabolic responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metabolic responders on FDG-PET scan after chemotherapy
Study: 30642285
Drug: Non-responders on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders on FDG-PET scan after chemotherapy
Study: 30642290
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg IV every 4 weeks) and Tremelimumab (75 mg IV every 4 weeks for a total of 4 doses) with SBRT to 2-5 metastases
Study: 30642372
Drug: Chiauranib 65
Normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiauranib 65 mg/day
Study: 30642372
Drug: Chiauranib 50
Normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiauranib 50 mg/day
Study: 30642372
Drug: Chiauranib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiauranib (various doses from 10 to 65 mg/day)
Study: 30642373
Drug: JS001 (anti-PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 (anti-PD-1 antibody)
Study: 30642415
Drug: Amisulpride (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (6 weeks treatment)
Study: 30642537
Drug: Afatinib (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (first-line treatment, modified starting dose of ≤30 mg for 31.1% of patients, 40 mg starting dose for others)
Study: 30642537
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg starting dose)
Study: 30642819
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg or 560 mg daily) + Nivolumab (3 mg/kg every 2 weeks)